Launch of Direct Acting Antivirals (DAA) radically transformed Hepatitis C (HCV) treatments.
Treatment capacity provided by the healthcare system has now become pivotal in achieving disease eradication by 2020 as planned by Italian NHS.
T8P supported the assessment of the impact of different HCV treatments organization models on outcome and costs to facilitate product adoption after launch.